Roth sticking with Allena Pharma despite selloff

Allena Pharmaceuticals

Roth Capital Partners believes Allena Pharmaceuticals (NASDAQ:ALNA) is getting “unnecessarily punished” on Nov. 7, despite positive URIROX-1 top-line study data, which included a high placebo response, smaller treatment effect and next steps for gaining regulatory approval.

Shares of Allena were quoted at $3.02, down $2.82, or 48%, in heavy trading at midday on Nov. 7.

“We believe URIROX-1 data tees up [study] URIROX-2 for success, with data expected in the second half of 2021,” writes analyst Yasmeen Rahimi. She continues to rate the stock at “buy” with a $31 price target.

Among other things, Ms. Rahimi said that with compelling results in bariatrics, Allena has multiple NDA paths forward. “Given URIROX-1 results, our survey results show a high enthusiasm among doctors for prescribing [Allena’s] reloxalise,” an orally administered enzyme for the treatment of hyperoxaluria.

Ms. Rahimi said the URIROX-1 readout serves as a considerable de-risking for URIROX-2. Both have the same primary endpoint and powering assumptions, and the URIROX-2 readout will also include 24-hour urine oxalate excretion data for weeks 16-to-24.

“In our view, this is a key piece of information for investors and regulators, as we believe the placebo rate will settle at its true value (less than 9%) the dampening of elevated compliance and attention to lifestyle among placebo patients at such a longer time point than URIROX-1,” she added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.